Related Experiment Video
Updated: Aug 6, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Complete Response to Concurrent Triplet Therapy in Low-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Case
Takashi Fujita1, Koki Kobayashi1, Gaku Hayashi1
1Department of Urology Gifu Prefectural Tajimi Hospital Tajimi Japan.
IJU Case Reports
|July 23, 2026
Summary
Triplet therapy, including androgen deprivation therapy (ADT), an androgen receptor pathway inhibitor, and docetaxel, shows promise for aggressive low-volume metastatic hormone-sensitive prostate cancer (mHSPC), achieving complete response in a case study.
Area of Science:
- Oncology
- Urology
Background:
- Metastatic hormone-sensitive prostate cancer (mHSPC) treatment typically involves androgen deprivation therapy (ADT).
- Triplet therapy combining ADT, androgen receptor pathway inhibitors, and docetaxel improves survival but its role in low-volume disease is unclear.
Purpose of the Study:
- To evaluate the efficacy of concurrent triplet therapy in a patient with aggressive, low-volume mHSPC.
Main Methods:
- A 68-year-old male with advanced prostate cancer (cT4N1M1b, low-volume mHSPC) received concurrent triplet therapy: ADT, darolutamide, and docetaxel.
- Treatment response was monitored via PSA levels and radiological imaging.
Main Results:
- The patient achieved a PSA nadir of 0.1 ng/mL within 2 months.
- Radiological complete response was observed at 4.5 months.
- At 7 months, PSA remained undetectable (<0.03 ng/mL) with no progression to castration-resistant prostate cancer (CRPC).
Conclusions:
- Concurrent triplet therapy can lead to a complete response in select patients with aggressive, low-volume mHSPC.
- This approach warrants further investigation for similar patient profiles.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...